Clinical Trial Update: Efficacy and Safety Study of Intravenous to Oral Solithromycin (CEM-101) Compared to Intravenous to Oral Moxifloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia [Phase 3]

View source ↗

Summary

Phase 3 efficacy and safety comparison of intravenous-to-oral solithromycin (CEM-101) versus moxifloxacin for community-acquired bacterial pneumonia; study comp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Community-acquired Bacterial Pneumonia

Drugs mentioned

• Moxifloxacin (moxifloxacin)
• Solithromycin (solithromycin)

Snippet

Sponsor: Melinta Therapeutics, Inc. | Conditions: Community-acquired Bacterial Pneumonia | Phase 3 | Status: COMPLETED